<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Ophthalmol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Ophthalmol</journal-id>
      <journal-title-group>
        <journal-title>BMC Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2415</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25947067</article-id>
      <article-id pub-id-type="pmc">4494801</article-id>
      <article-id pub-id-type="publisher-id">38</article-id>
      <article-id pub-id-type="doi">10.1186/s12886-015-0038-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary extranodal marginal zone B-cell lymphoma with diffuse uveal involvement and focal infiltration of the trabecular meshwork: a case report and review of literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>Xinxiao</given-names>
          </name>
          <address>
            <email>drxinxiaogao@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Bin</given-names>
          </name>
          <address>
            <email>libin43_99@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>You</surname>
            <given-names>Qisheng</given-names>
          </name>
          <address>
            <email>qishengbio@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Peng</surname>
            <given-names>Xiaoyan</given-names>
          </name>
          <address>
            <email>drpengxy@yeah.net</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Beijing Institute of Ophthalmology, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, 17 Hougou Lane, Chongnei Street, Beijing, 100005 China </aff>
        <aff id="Aff2"><label/>Department of Ophthalmology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>7</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>7</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>48</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>11</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>4</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Gao et al.; licensee BioMed Central. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Primary extranodal marginal zone lymphoma (EMZL) of the uvea is a rare condition and diagnosis may be challenging. We aim to report the clinical, histopathologic and immunohistochemical findings in a case of primary EMZL with diffuse uveal involvement and focal infiltration of the trabecular meshwork.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 38-year-old male presented with 2-year progressive vision loss in the right eye. Fundus examination showed choroidal thickening with diffuse retinal pigment epithelium (RPE) changes and inferior exudative retinal detachment. Ultrasonography revealed low-reflective masses with diffuse thickening of the choroid involving the optic nerve and orbit. Despite treatment with steroids, his symptoms progressed over time. One year later, visual acuity of the right eye markedly decreased to no light perception and enucleation was performed. Histopathological findings revealed infiltrates of malignant cells in the choroid, iris, ciliary body and trabecular meshwork. Immunohistochemistry confirmed the diagnosis of primary uveal EMZL.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This is the first case reporting primary EMZL diffusely involving the uvea with focal infiltration of the trabecular meshwork.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Ophthalmic lymphomas account for approximately 10% of all extranodal malignant lymphomas [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. The major subtype of ophthalmic lymphoma is extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT) [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>]. It presents an indolent clinical course and usually involves the conjunctiva, lacrimal gland, and orbit. Intraocular choroidal involvement is a rare condition. Primary iris and ciliary body EMZL are exceptionally rare with only a handful of cases reported in the literature [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>In this study, we present a rare case of EMZL diffusely involving the uvea with focal involvement of trabecular meshwork and review of reported cases. The study was approved by institutional review committee of Beijing Tongren Hospital, Capital Medical University and was conducted in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from the patient.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>In November 2012, a 38-year-old male presented with 2-year progressive vision loss in his right eye. He was referred to our clinic for a choroidal lesion with subretinal fluid in the right eye. He had been generally healthy and denied any significant past medical history including diabetes mellitus and hypertension. Since 2010, the onset of the vision decrease, a flat serous retinal detachment in his right eye was detected by a local ophthalmologist. However, no treatment was given, for the diagnosis was unclear at that moment. After several outpatient follow-ups, the disease progressed gradually. One year later, he visited another ophthalmologist for a second opinion. At that time, a choroidal mass with associated serous retinal detachment was detected, yet no treatment was performed, for the diagnosis remained unclear. At his initial visit to our institute, best corrected visual acuity was 20/200 in the right eye and 20/16 in the left eye. Intraocular pressure of both eyes was within normal limits. Examination of the left eye was unremarkable. Right eye anterior segment was normal. Fundus examination revealed choroidal thickening with diffuse retinal pigment epithelium (RPE) changes and inferior exudative retinal detachment (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1A</xref>). Fluorescein angiography showed nonspecific leakage at the level of the RPE and formation of macular edema, combined with thickening of the choroid and serous retinal detachment (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2A-B</xref>). Ultrasonography showed low-reflective masses with diffuse thickening of the choroid and involvement of optic nerve and orbit (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3A-B</xref>). A suspicious diagnosis of posterior scleritis or choroidal hemangioma was made. Retrobulbar twenty-milligram triamcinolone acetonide was then given. However, the ocular findings were unchanged. One week later, he received experimental treatment of intravitreal ranibizumab.<fig id="Fig1"><label>Figure 1</label><caption><p>Fundus colour photograph. <bold>(A)</bold> Choroidal thickening was shown, with diffuse retinal pigment epithelium (RPE) changes and inferior exudative retinal detachment. <bold>(B)</bold> Deteriorated retinal detachment was demonstrated.</p></caption><graphic xlink:href="12886_2015_38_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>Fluorescence angiography. <bold>(A)</bold> Early-phase fluorescein angiogram of right eye. <bold>(B)</bold> Late phase showed macular edema and nonspecific leakage at the level of the RPE.</p></caption><graphic xlink:href="12886_2015_38_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>Ultrasonography. <bold>(A)</bold> B scan showed diffuse thickening of choroid (arrow) with low-reflective retrobulbar masses (arrow heads). <bold>(B)</bold> Colour Doppler imaging revealed choroidal infiltration and involvement of optic nerve and orbit.</p></caption><graphic xlink:href="12886_2015_38_Fig3_HTML" id="MO3"/></fig></p>
      <p>The patient was loss to follow up until 6&#xA0;months after intravitreal ranibizumab injection. Magnetic resonance imaging (MRI) of the orbits confirmed extensive choroidal thickening involving the optic disc with a height of 0.37&#xA0;cm. Two lobulated soft tissue masses were seen around the optic nerve. Fundoscopy revealed deteriorated retinal detachment (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1B</xref>). The patient and his family refused to undergo aggressive treatment, including biopsy. One year later, patient returned to our clinic with visual acuity of no light perception on the right eye. Since the etiology of the mass was uncertain, enucleation was performed after written informed consent was obtained from the patient. Histopathology revealed the choroid, iris, ciliary body and trabecular meshwork infiltrated with malignant cells (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4A</xref>). Orbit and optic nerve were also involved (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4B</xref>). Intra-retinal exudates were noted and the retina was detached with subretinal exudation and some foamy cells. Fibrous membrane was noted between the retina and a diffusely thickened choroid. This was found to be heavily pigmented lymphocytes with small irregular nuclei. Extension of malignant cells to the retrobulbar tissue was also noted (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4C-D</xref>). Immunohistochemistry showed positive staining for CD5, CD20, CD23, CD38, CD79a, CD45RO, Bcl-2, Kappa, Lambda, LCA, Vimentin and Ki-67 (5%-10% positive cells), whereas CD10, Bcl-6 and Cyclin D1 were negative (Figure&#xA0;<xref rid="Fig5" ref-type="fig">5A-H</xref>). The diagnosis of primary uveal EMZL was made based on the histomorphology and immunohistochemistry examinations. The patient underwent a systemic work up including positron emission tomography and bone marrow aspiration smears. The results were negative.<fig id="Fig4"><label>Figure 4</label><caption><p>Histologic features of EMZL. <bold>(A)</bold> Low power magnification showing extensive infiltration of uvea, including choroid, iris, ciliary body and trabecular meshwork (HE; magnification&#x2009;&#xD7;&#x2009;20). <bold>(B)</bold> Higher power magnification demonstrating choroidal infiltration by tumor cells, with involvement of optic nerve and orbit (HE; magnification&#x2009;&#xD7;&#x2009;40). <bold>(C)</bold> Increased magnification illustrating the infiltrate of tumor cells with heavily pigmented lymphocytes in choroid and extension of malignant cells to retrobulbar tissue through sclera emissary canal (HE; magnification&#x2009;&#xD7;&#x2009;40). <bold>(D)</bold> High power magnification revealing an infiltrate of atypical lymphocytes with small irregular nuclei (HE; magnification&#x2009;&#xD7;&#x2009;400).</p></caption><graphic xlink:href="12886_2015_38_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Figure 5</label><caption><p>Immunohistochemical expression of EMZL. <bold>(A)</bold> Tumour cells positive for CD20. <bold>(B)</bold> Positivity for CD79a. <bold>(C)</bold> Positivity for CD5. <bold>(D)</bold> Positivity for CD45RO. <bold>(E)</bold> Positivity for Bcl-2. <bold>(F)</bold> Positivity for Ki67. <bold>(G)</bold> Positivity for LCA. <bold>(H)</bold> Positivity for Vimentin.</p></caption><graphic xlink:href="12886_2015_38_Fig5_HTML" id="MO5"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>Primary uveal lymphoma has been named as &#x201C;uveal lymphosarcoma&#x201D;, &#x201C;reactive lymphoid hyperplasia&#x201D; and &#x201C;uveal pseudotumours&#x201D; in the past [<xref ref-type="bibr" rid="CR8">8</xref>-<xref ref-type="bibr" rid="CR10">10</xref>]. In 1994, based on the findings of the International Lymphoma Study Group, the term &#x2018;extranodal marginal zone B cell lymphoma&#x2019; was proposed by the Revised European American Lymphoma (REAL) classification to incorporate both mucosa- and non-mucosa-associated &#x2018;MALT&#x2019; lymphomas [<xref ref-type="bibr" rid="CR11">11</xref>]. More recently, primary uveal lymphoma was suggested to be accurately subtyped as EMZL of MALT type (WHO lymphoma classification), since its morphological, immunophenotypical, and clinical features were identical to those of EMZL-MALT elsewhere [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p>According to the REAL classification, only 61 EMZL cases (including the present case) have been reported since 1994 (More details can be found in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR12">12</xref>-<xref ref-type="bibr" rid="CR23">23</xref>]. These cases included 24 male and 13 female (patient gender was not reported in 24 cases). The age of the patients at presentation ranged from 33 to 85&#xA0;years. Majority of the cases involved the choroid. Primary iris lymphomas were unusual, with only 2 cases described [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>]. And only a single case of primary lymphomas limited to the ciliary body has been reported [<xref ref-type="bibr" rid="CR7">7</xref>]. Most of these cases involved extraocular tissue, with only 10 cases having no extraocular extension [<xref ref-type="bibr" rid="CR24">24</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Literature review of EMZL since 1994</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<bold>No. of cases</bold>
</th><th>
<bold>Ref/Year</bold>
</th><th>
<bold>Age/Gender</bold>
</th><th>
<bold>Eye/Initial BCVA</bold>
</th><th>
<bold>Extraocular extension</bold>
</th><th>
<bold>Site</bold>
</th><th>
<bold>Pathology findings</bold>
</th><th>
<bold>Treatment</bold>
</th><th>
<bold>Systemic work-up</bold>
</th><th>
<bold>Follow-up (months)</bold>
</th></tr></thead><tbody><tr><td>1</td><td>5/2000</td><td>51/F</td><td>L/0.5</td><td>N</td><td>Iris</td><td>CD20+, CD19+, Kappa LC+</td><td>Radiotherapy Enucleation</td><td>N</td><td>72</td></tr><tr><td>2</td><td>12/2002</td><td>63/M</td><td>NA/NLP</td><td>N</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138-, Vs38c+, Kappa LC-, Lambda LC+, IgM-, IgD-</td><td>Enucleation</td><td>N</td><td>156</td></tr><tr><td>3</td><td/><td>40/F</td><td>NA/NLP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138-, Vs38c-, Kappa LC-, Lambda LC+, IgM+, IgD-</td><td>Enucleation, Radiotherapy</td><td>Y</td><td>300</td></tr><tr><td>4</td><td/><td>40/M</td><td>NA/HM</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138&#xB1;, Vs38c+, Kappa LC+, Lambda LC-, IgM+, IgD-</td><td>Enucleation, Radiotherapy</td><td>N</td><td>216</td></tr><tr><td>5</td><td/><td>45/M</td><td>NA/LP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138+, Vs38c+, Kappa LC-, Lambda LC+, IgM+, IgD-</td><td>Enucleation, Radiotherapy</td><td>N</td><td>120</td></tr><tr><td>6</td><td/><td>64/M</td><td>NA/LP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38-, CD138+, Vs38c+, Kappa LC-, Lambda LC+, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>108</td></tr><tr><td>7</td><td/><td>33/M</td><td>NA/CF</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138-, Vs38c+, Kappa LC-, Lambda LC+, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>84</td></tr><tr><td>8</td><td/><td>63/M</td><td>NA/0.05</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138-, Vs38c+, Kappa LC+, Lambda LC-, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>60</td></tr><tr><td>9</td><td/><td>59/F</td><td>NA/LP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138-, Vs38c-, Kappa LC-, Lambda LC-, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>Unknown</td></tr><tr><td>10</td><td/><td>66/M</td><td>NA/LP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138-, Vs38c-, Kappa LC-, Lambda LC+, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>Unknown</td></tr><tr><td>11</td><td/><td>73/M</td><td>NA/LP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138+, Vs38c-, Kappa LC+, Lambda LC-, IgM+, IgD-</td><td>Enucleation</td><td>Y</td><td>2</td></tr><tr><td>12</td><td/><td>81/M</td><td>NA/LP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138+, Vs38c-, Kappa LC-, Lambda LC+, IgM+, IgD-</td><td>Enucleation</td><td>Y</td><td>180</td></tr><tr><td>13</td><td/><td>73/F</td><td>NA/NLP</td><td>Y</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138+, Vs38c+, Kappa LC+, Lambda LC-, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>Unknown</td></tr><tr><td>14</td><td/><td>63/M</td><td>NA/N LP</td><td>N</td><td>Uvea</td><td>CD79a+, CD20+, BSAP+, MUM1+, CD38+, CD138+, Vs38c+, Kappa LC+, Lambda LC-, IgM+, IgD-</td><td>Enucleation</td><td>N</td><td>120</td></tr><tr><td>15</td><td>6/2003</td><td>83/F</td><td>L/0.2</td><td>N</td><td>Iris</td><td>CD20/l-26+, CD79a+, CD3-, CD45RO/UCHL-1-</td><td>Radiotherapy</td><td>N</td><td>8</td></tr><tr><td>16</td><td>13/2005</td><td>45/M</td><td>L/0.16</td><td>N</td><td>Choroid</td><td>CD79a+, CD20+, BCL2+, CD43+, CD3-, CD5-, CD23-, CyclinD1-, Kappa LC+, IgM+, Ki67 10%</td><td>Radiotherapy</td><td>N</td><td>17</td></tr><tr><td>17</td><td>7/2008</td><td>84/F</td><td>R/0.63</td><td>N</td><td>Ciliary body</td><td>CD79a+, CD20+, CD43&#xB1;, IgM+, CD5-, CD23-, CyclinD1-, Ki-67 5%-15%</td><td>Radiotherapy</td><td>N</td><td>4</td></tr><tr><td>18</td><td>14/2008</td><td>57/F</td><td>L/0.5</td><td>Conjunctiva</td><td>Choroid</td><td>CD20+, Bcl2+, CD5-, CD23-, CD43-, Bcl6-, CyclinD1-, Kappa LC+</td><td>Radiotherapy</td><td>N</td><td>6</td></tr><tr><td>19</td><td/><td>85/M</td><td>NA</td><td>N</td><td>Choroid</td><td>CD20+, CD19+, CD5-, Lambda LC+</td><td>Radiotherapy</td><td>N</td><td>3</td></tr><tr><td>20</td><td>15/2009</td><td>68/M</td><td>L/HM</td><td>Conjunctiva</td><td>Choroid</td><td>CD20+, CD3&#xB1;, Lambda LC+, kappa LC-</td><td>Radiotherapy</td><td>N</td><td>60</td></tr><tr><td>21</td><td>16/2010</td><td>80/M</td><td>R/0.1</td><td>Epibulbar tumor</td><td>Iris, ciliary body, choroid</td><td>CD3-, CD5-, CD10-, CD20+, CD23-, CD38-, CD43&#xB1;, CD56-, CD57-, CD79a+, CD138-, Bcl-2+, Bcl-6-, CyclinD1-, IgM-, Kappa LC-, Lambda LC-, Ki-67&#x2009;&lt;&#x2009;10%</td><td>Enucleation</td><td>N</td><td>28</td></tr><tr><td>22</td><td>17/2011</td><td>49/M</td><td>R/CF</td><td>Orbit, sphenoid bone</td><td>Choroid</td><td>CD20+, CD3-, CD5-, CD10-</td><td>Chemotherapy Radiotherapy</td><td>N</td><td>NA</td></tr><tr><td>23</td><td>18/2012</td><td>62/M</td><td>L/0.67</td><td>Orbit, optic nerve</td><td>Choroid</td><td>CD79+, CD20+, BCL2+, CD10+ (focally), CyclinD1-</td><td>Radiotherapy</td><td>N</td><td>6</td></tr><tr><td>24</td><td>19/2013</td><td>73/F</td><td>NA/0.625</td><td>Conjunctiva, orbit</td><td>Choroid</td><td>CD20+++, CD5+, Bcl6+, CyclinD1+, Kappa LC+, Lambda LC -, Ki67 5-10%</td><td>Radiotherapy</td><td>N</td><td>6</td></tr><tr><td>25</td><td/><td>46/M</td><td>NA/0.2</td><td>N</td><td>Choroid</td><td>CD20+++, CD79a+++, CD3+</td><td>Chemotherapy</td><td>N</td><td>84</td></tr><tr><td>26</td><td/><td>63/M</td><td>NA/0.16</td><td>Conjunctiva</td><td>Choroid</td><td>CD20+++, CD5+, CD10-, Bcl6-, CyclinD1-, Ki67 50%</td><td>Radiotherapy Chemotherapy</td><td>N</td><td>60</td></tr><tr><td>27</td><td/><td>54/F</td><td>NA/0.625</td><td>N</td><td>Choroid</td><td>CD20+++, CD5+, CD23-, Bcl6-, CyclinD1-, Kappa LC+, Lambda LC+++</td><td>Radiotherapy</td><td>N</td><td>144</td></tr><tr><td>28</td><td/><td>64/F</td><td>NA/0.005</td><td>Orbit</td><td>Choroid</td><td>CD20+++, CD5+, CD10-, CD138+, Bcl6-, CyclinD1-, Kappa LC+, Lambda LC+++, Ki67 5%</td><td>Radiotherapy</td><td>N</td><td>12</td></tr><tr><td>29</td><td/><td>54/F</td><td>NA/0.5</td><td>Orbit</td><td>Choroid</td><td>CD20+, CD5+, CD3+, kappa LC-, Lambda LC-</td><td>Radiotherapy Chemotherapy</td><td>N</td><td>120</td></tr><tr><td>30</td><td/><td>40/M</td><td>NA/0.8</td><td>N</td><td>Choroid</td><td>CD20+, Bcl2-, Kappa LC+</td><td>Radiotherapy Chemotherapy</td><td>N</td><td>156</td></tr><tr><td>31</td><td/><td>53/F</td><td>NA/0.1</td><td>Lacrymal gland</td><td>Choroid</td><td>CD20++, CD3+, CD5+, CD8+, Bcl2+++, Bcl6++, Kappa LC+++, Lambda LC+, Ki67-</td><td>Chemotherapy</td><td>N</td><td>53</td></tr><tr><td>32</td><td/><td>57/M</td><td>NA/0.32</td><td>Conjunctiva</td><td>Choroid</td><td>CD20+++, CD5+, CD23-, Bcl6+, Kappa LC-, Lambda LC-, Ki67 20%</td><td>Chemotherapy</td><td>N</td><td>33</td></tr><tr><td>33</td><td>20/2013</td><td>71/M</td><td>L/0.2</td><td>Conjunctiva, optic nerve</td><td>Choroid</td><td>CD20+, CD43+, Bcl2+, CD3-</td><td>Chemotherapy</td><td>N</td><td>12</td></tr><tr><td>34</td><td>21/2013</td><td>71 /F</td><td>L/0.5</td><td>Conjunctiva</td><td>Iris, choroid</td><td>NA</td><td>Radiotherapy</td><td>N</td><td>44</td></tr><tr><td>35</td><td/><td>71/M</td><td>R/0.05</td><td>Conjunctiva</td><td>Iris, choroid</td><td>NA</td><td>Radiotherapy</td><td>N</td><td>36</td></tr><tr><td>36</td><td/><td>75/M</td><td>R/0.5</td><td>Conjunctiva, orbit</td><td>Iris, ciliary body, choroid</td><td>NA</td><td>Radiotherapy</td><td>Unknown</td><td>0</td></tr><tr><td>37-52</td><td>22/2014</td><td>NA</td><td>NA</td><td>NA</td><td>Choroid</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>53-60</td><td>23/2014</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>61</td><td>Present case</td><td>38/M</td><td>R/0.1</td><td>Orbit, optic nerve</td><td>Iris, ciliary body, choroid, trabecular meshwork</td><td>CD5+, CD10-, CD20+, CD23+, CD38+, CD79a+, Bcl-2+, Bcl-6-, CyclinD1-, Kappa LC+, Lambda LC+, Ki-67 5%-10%</td><td>Enucleation</td><td>N</td><td>18</td></tr></tbody></table><table-wrap-foot><p>BCVA, best corrected visual acuity; CF, counting figure; F, female; HM, hand motion; L, left; LP, light perception; M, male; N, no; NA, not available; NLP, no light perception; R, right; Y, yes.</p></table-wrap-foot></table-wrap></p>
      <p>Clinical diagnosis of early EMZL may be difficult. Uveal lymphoma can masquerade as amelanotic uveal melanoma, uveal metastases, uveal effusion syndrome, posterior scleritis, and various uveitities. This presents a significant diagnostic challenge [<xref ref-type="bibr" rid="CR25">25</xref>-<xref ref-type="bibr" rid="CR27">27</xref>]. Delays in the diagnosis of uveal lymphoma are common for its insidious and nonspecific onset [<xref ref-type="bibr" rid="CR16">16</xref>]. Loriaut et al. reported a series of choroidal and adnexal extranodal marginal zone B-cell lymphoma. In their 9 cases, the mean time to diagnosis was 12&#xA0;months after onset and the longest period for diagnosis delay was 24&#xA0;months [<xref ref-type="bibr" rid="CR19">19</xref>]. Typical presenting symptoms such as recurrent episodes of blurred vision, painless visual loss and metamorphopsia, may result from macular serous retinal detachment [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR12">12</xref>]. The characteristic findings include clear vitreous, choroidal thickening and no involvement of central nervous system. Imaging techniques, including ultrasonography and orbital MRI, are valuable to detect extraocular involvement [<xref ref-type="bibr" rid="CR28">28</xref>]. Histopathologic study with immunohistochemical stains remains mandatory to make an accurate diagnosis and classification [<xref ref-type="bibr" rid="CR12">12</xref>]. Biopsy of the episcleral tumour nodule or an intraocular biopsy is commonly required to determine the nature of the uveal mass [<xref ref-type="bibr" rid="CR29">29</xref>]. However, it is difficult to obtain a tissue sample. In some inconclusive or late-stage cases, it may be necessary to perform enucleation for the definitive diagnosis [<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR30">30</xref>]. In the present case, absence of any evidence of systemic disease at presentation and during 2&#xA0;years of follow-up, could have facilitated the diagnosis of primary EMZL of the uvea.</p>
      <p>The exact incidence of primary iris and ciliary body lymphoma remains unknown because only a small number of cases have been reported. This may be due to the evidence that most iris and ciliary body infiltrations have been confirmed only after enucleation or on postmortem histopathology [<xref ref-type="bibr" rid="CR31">31</xref>]. There were only two reports with diffuse uveal involvement in our literature review. However, no infiltration of trabecular meshwork was mentioned [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR21">21</xref>]. In this case we report diffuse uveal involvement (choroid, ciliary body and iris) with focal trabecular meshwork infiltration, which is the first report to the best of our knowledge. However, no secondary glaucoma was found in this case. The mechanism was uncertain and infiltration in early stage may be one of the possible explanations. Our case also masqueraded as posterior scleritis or choroidal hemangioma, presenting diffuse thickened choroid with optic nerve and orbit involvement.</p>
      <p>To date, there are no consensus to the optimal treatment for uveal lymphoma due to the small number of such patients and short duration of follow-up. Some authors preferred low-dose external radiotherapy for uveal lymphoma on the basis of satisfactory disease control and few side effects [<xref ref-type="bibr" rid="CR12">12</xref>]. Although conventional external radiotherapy remains the most frequently used modality, exclusive chemotherapy based on anti-CD20 regimen increasingly becomes one of the treatment choices [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR32">32</xref>].</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>In summary, uveal EMZL may present with various features and we report a rare case with diffuse involvement of the uveal and focal trabecular meshwork infiltration. The diagnosis of uveal EMZL is challenging and commonly delayed due to its insidious and nonspecific onset. Early clinical recognition, tissue biopsy, and expert cytologic assessment are critical to achieve early diagnosis and better clinical outcomes. Despite the rarity, uveal EMZL should be included in the differential diagnosis of uveal inflammation or tumors, particularly in patients with persistent signs and symptoms. Non-resolving or recurrent masquerade syndromes not responding to standard treatment should lead to prompt biopsy [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>EMZL</term>
          <def>
            <p>Extranodal marginal zone lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>RPE</term>
          <def>
            <p>Retinal pigment epithelium</p>
          </def>
        </def-item>
        <def-item>
          <term>MALT</term>
          <def>
            <p>Mucosa-associated lymphoid tissue</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>XXG performed the literature review and drafted the manuscript. BL carried out HE and immunohistochemistry stain and interpreted the patient&#x2019;s data. QSY collected clinical information of the patient. XYP supplied the case of the patient and made the final diagnosis of this disease. All authors have read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We do not have someone to acknowledge to.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Occurrence and prognosis of extranodal lymphomas</article-title>
          <source>Cancer</source>
          <year>1972</year>
          <volume>29</volume>
          <fpage>252</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(197201)29:1&lt;252::AID-CNCR2820290138&gt;3.0.CO;2-#</pub-id>
          <pub-id pub-id-type="pmid">5007387</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coupland</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Damato</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Lymphomas involving the eye and the ocular adnexa</article-title>
          <source>Curr Opin Ophthalmol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>523</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">17065920</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>White</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Ferry</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Grove</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Ocular adnexal lymphoma: a clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type</article-title>
          <source>Ophthalmology</source>
          <year>1995</year>
          <volume>102</volume>
          <fpage>1994</fpage>
          <lpage>2006</lpage>
          <pub-id pub-id-type="doi">10.1016/S0161-6420(95)30764-6</pub-id>
          <pub-id pub-id-type="pmid">9098307</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitcup</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>de Smet</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Palestine</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Burnier</surname>
              <given-names>M</given-names>
              <suffix>Jr</suffix>
            </name>
            <etal/>
          </person-group>
          <article-title>Intraocular lymphoma: clinical and histopathologic diagnosis</article-title>
          <source>Ophthalmology</source>
          <year>1993</year>
          <volume>100</volume>
          <fpage>1399</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1016/S0161-6420(93)31469-7</pub-id>
          <pub-id pub-id-type="pmid">8371930</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Velez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>de Smet</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Whitcup</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nussenblatt</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>CC</given-names>
            </name>
          </person-group>
          <article-title>Iris involvement in primary intraocular lymphoma: report of two cases and review of the literature</article-title>
          <source>Surv Ophthalmol</source>
          <year>2000</year>
          <volume>44</volume>
          <fpage>518</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6257(00)00118-1</pub-id>
          <pub-id pub-id-type="pmid">10906383</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tanihara</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>A case of primary B-cell type non-Hodgkin lymphoma originating in the iris</article-title>
          <source>Am J Ophthalmol</source>
          <year>2003</year>
          <volume>136</volume>
          <fpage>380</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="doi">10.1016/S0002-9394(03)00324-6</pub-id>
          <pub-id pub-id-type="pmid">12888075</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coupland</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Damato</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Understanding intraocular lymphomas</article-title>
          <source>Clin Experiment Ophthalmol</source>
          <year>2008</year>
          <volume>36</volume>
          <fpage>564</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-9071.2008.01843.x</pub-id>
          <pub-id pub-id-type="pmid">18954321</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Triebenstein</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Ein Beitrag zur Frage der aleukamischen Augenveranderungen</article-title>
          <source>Kin Monatsbl Augenheilkd</source>
          <year>1920</year>
          <volume>64</volume>
          <fpage>825</fpage>
          <lpage>36</lpage>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryan</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Zimmerman</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Reactive lymphoid hyperplasia. An unusual form of intraocular pseudotumor</article-title>
          <source>Trans Am Acad Ophthalmol Otolaryngol</source>
          <year>1972</year>
          <volume>76</volume>
          <fpage>652</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">4126438</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cockerham</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Hidayat</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Bijwaard</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Sheng</surname>
              <given-names>ZM</given-names>
            </name>
          </person-group>
          <article-title>Re-evaluation of &#x2018;reactive lymphoid hyperplasia of the uvea&#x2019;: an immunohistochemical and molecular analysis of 10 cases</article-title>
          <source>Ophthalmology</source>
          <year>2000</year>
          <volume>107</volume>
          <fpage>151</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/S0161-6420(99)00025-1</pub-id>
          <pub-id pub-id-type="pmid">10647734</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Cleary</surname>
              <given-names>ML</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A revised European&#x2013;American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>84</volume>
          <fpage>1361</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">8068936</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coupland</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Foss</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Hidayat</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Cockerham</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Hummel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases</article-title>
          <source>J Pathol</source>
          <year>2002</year>
          <volume>197</volume>
          <fpage>333</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1002/path.1130</pub-id>
          <pub-id pub-id-type="pmid">12115879</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coupland</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Joussen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Anastassiou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2005</year>
          <volume>243</volume>
          <fpage>482</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1007/s00417-004-1050-4</pub-id>
          <pub-id pub-id-type="pmid">15586289</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuller</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Sweetenham</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schoenfield</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Uveal lymphoma: a variant of ocular adnexal lymphoma</article-title>
          <source>Leuk Lymphoma</source>
          <year>2008</year>
          <volume>49</volume>
          <fpage>2393</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1080/10428190802517781</pub-id>
          <pub-id pub-id-type="pmid">19052995</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a-Alvarez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Saornil</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>M&#xE9;ndez</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez-Lara</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Extranodal B-cell uveal lymphoma with extraocular involvement</article-title>
          <source>Can J Ophthalmol</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>213</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.3129/i08-176</pub-id>
          <pub-id pub-id-type="pmid">19491963</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rasic&#x2019;</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Stankovic&#x2019;</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Terzic&#x2019;</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kovacevic&#x2019;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Koturovic&#x2019;</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Markovic&#x2019;</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report</article-title>
          <source>Med Oncol</source>
          <year>2010</year>
          <volume>27</volume>
          <fpage>1010</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1007/s12032-009-9325-6</pub-id>
          <pub-id pub-id-type="pmid">19816817</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tagami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sekimukai</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Azumi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Uveal extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type with concomitant extraocular lesions in a Japanese man</article-title>
          <source>Jpn J Ophthalmol</source>
          <year>2011</year>
          <volume>55</volume>
          <fpage>585</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s10384-011-0013-7</pub-id>
          <pub-id pub-id-type="pmid">21717179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baryla</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ong</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sheidow</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Choroidal lymphoma with orbital and optic nerve extension: case and review of literature</article-title>
          <source>Can J Ophthalmol</source>
          <year>2012</year>
          <volume>47</volume>
          <fpage>79</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcjo.2011.12.017</pub-id>
          <pub-id pub-id-type="pmid">22333857</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loriaut</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Charlotte</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bodaghi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Decaudin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leblond</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fardeau</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Choroidal and adnexal extranodal marginal zone B-cell lymphoma: presentation, imaging findings, and therapeutic management in a series of nine cases</article-title>
          <source>Eye (Lond)</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>828</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1038/eye.2013.74</pub-id>
          <pub-id pub-id-type="pmid">23598677</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rospond-Kubiak</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Koci&#x119;cki</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stopa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Primary uveal lymphoma effectively managed with oral chlorambucil: a case report</article-title>
          <source>J Med Case Rep</source>
          <year>2013</year>
          <volume>7</volume>
          <fpage>173</fpage>
          <pub-id pub-id-type="doi">10.1186/1752-1947-7-173</pub-id>
          <pub-id pub-id-type="pmid">23822827</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mashayekhi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shields</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Shields</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Iris involvement by lymphoma: a review of 13 cases</article-title>
          <source>Clin Experiment Ophthalmol</source>
          <year>2013</year>
          <volume>41</volume>
          <fpage>19</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-9071.2012.02811.x</pub-id>
          <pub-id pub-id-type="pmid">22594613</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aronow</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Portell</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Sweetenham</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes</article-title>
          <source>Ophthalmology</source>
          <year>2014</year>
          <volume>121</volume>
          <fpage>334</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2013.09.004</pub-id>
          <pub-id pub-id-type="pmid">24144449</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mashayekhi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shukla</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Shields</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Shields</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Choroidal lymphoma: clinical features and association with systemic lymphoma</article-title>
          <source>Ophthalmology</source>
          <year>2014</year>
          <volume>121</volume>
          <fpage>342</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2013.06.046</pub-id>
          <pub-id pub-id-type="pmid">23978622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagoo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Swampillai</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Amin</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Plowman</surname>
              <given-names>PN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary intraocular lymphoma</article-title>
          <source>Surv Ophthalmol</source>
          <year>2014</year>
          <volume>59</volume>
          <fpage>503</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1016/j.survophthal.2013.12.001</pub-id>
          <pub-id pub-id-type="pmid">24560125</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Jampol</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Cantrill</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>Intraocular lymphoma presenting as retinal vasculitis</article-title>
          <source>Surv Ophthalmol</source>
          <year>1994</year>
          <volume>39</volume>
          <fpage>133</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1016/0039-6257(94)90158-9</pub-id>
          <pub-id pub-id-type="pmid">7801221</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gill</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Jampol</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Variations in the presentation of primary intraocular lymphoma: case reports and a review</article-title>
          <source>Surv Ophthalmol</source>
          <year>2001</year>
          <volume>45</volume>
          <fpage>463</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6257(01)00217-X</pub-id>
          <pub-id pub-id-type="pmid">11425352</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rothova</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ooijman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kerkhoff</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Van Der Lelij</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lokhorst</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Uveitis masquerade syndromes</article-title>
          <source>Ophthalmology</source>
          <year>2001</year>
          <volume>108</volume>
          <fpage>386</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="doi">10.1016/S0161-6420(00)00499-1</pub-id>
          <pub-id pub-id-type="pmid">11158819</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Read</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Zamir</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>NA</given-names>
            </name>
          </person-group>
          <article-title>Neoplastic masquerade syndromes</article-title>
          <source>Surv Ophthalmol</source>
          <year>2002</year>
          <volume>47</volume>
          <fpage>81</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6257(01)00305-8</pub-id>
          <pub-id pub-id-type="pmid">11918892</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coutinho</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Muccioli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Belfort</surname>
              <given-names>R</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sant&#x2019; Anna</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Burnier</surname>
              <given-names>MN</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Extranodal B-cell lymphoma of the uvea: a case report</article-title>
          <source>Can J Ophthalmol</source>
          <year>2005</year>
          <volume>40</volume>
          <fpage>623</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/S0008-4182(05)80058-4</pub-id>
          <pub-id pub-id-type="pmid">16391629</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>G&#xFC;nd&#xFC;z</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shields</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Shields</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Eagle</surname>
              <given-names>RC</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Diniz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transscleral choroidal biopsy in the diagnosis of choroidal lymphoma</article-title>
          <source>Surv Ophthalmol</source>
          <year>1999</year>
          <volume>43</volume>
          <fpage>551</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6257(99)00041-7</pub-id>
          <pub-id pub-id-type="pmid">10416797</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qualman</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Mendelsohn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>WR</given-names>
            </name>
          </person-group>
          <article-title>Intraocular lymphomas: natural history based on a clinicopathologic study of eight cases and review of the literature</article-title>
          <source>Cancer</source>
          <year>1983</year>
          <volume>52</volume>
          <fpage>878</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19830901)52:5&lt;878::AID-CNCR2820520523&gt;3.0.CO;2-D</pub-id>
          <pub-id pub-id-type="pmid">6347357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paik</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>BO</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>GS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma</article-title>
          <source>Ann Hematol</source>
          <year>2012</year>
          <volume>91</volume>
          <fpage>1393</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="doi">10.1007/s00277-012-1469-3</pub-id>
          <pub-id pub-id-type="pmid">22543827</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teoh</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic techniques for inflammatory eye disease: past, present and future: a review</article-title>
          <source>BMC Ophthalmol</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>41</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2415-13-41</pub-id>
          <pub-id pub-id-type="pmid">23926885</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
